Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Paola GuglielmelliCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy.ORCID 0000-0003-1809-284X
Arianna GhirardiFROM Research Foundation, Papa Giovanni XXIII Hospital Bergamo Italy.
Alessandra CarobbioFROM Research Foundation, Papa Giovanni XXIII Hospital Bergamo Italy.ORCID 0000-0001-9664-7084
Arianna MasciulliFROM Research Foundation, Papa Giovanni XXIII Hospital Bergamo Italy.
Lucrezia MorroneCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy.
Barbara MoraDepartment of Hematology and Oncology, University of Milan Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy.ORCID 0000-0002-6325-3916
Elisa RumiDivision of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Department of Molecular Medicine University of Pavia Pavia Italy.ORCID 0000-0002-7572-9504
Ana TrigueroDepartment of Hematology Hospital Clínic de Barcelona Barcelona Spain.ORCID 0000-0002-9895-9644
Maria C FinazziDepartment of Oncology-Hematology University of Milan and Papa Giovanni XXIII Hospital Bergamo Italy.ORCID 0000-0002-1857-5836
Helna PetterssonDivision of Hematology NU Hospital Group Uddevalla Sweden.
Valentina BoldriniCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy.
Daniele VanniDivision of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Department of Molecular Medicine University of Pavia Pavia Italy.
Alessandro RambaldiDepartment of Oncology-Hematology University of Milan and Papa Giovanni XXIII Hospital Bergamo Italy.ORCID 0000-0002-3739-7502
Francesco PassamontiDepartment of Hematology and Oncology, University of Milan Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy.ORCID 0000-0001-8068-5289
Alberto Alvarez-LarrànDepartment of Hematology Hospital Clínic de Barcelona Barcelona Spain.ORCID 0000-0001-6387-4619
Bjorn AndreassonDivision of Hematology NU Hospital Group Uddevalla Sweden.
Alessandro M VannucchiCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy.ORCID 0000-0001-5755-0730
Tiziano BarbuiFROM Research Foundation, Papa Giovanni XXIII Hospital Bergamo Italy.ORCID 0000-0003-2747-6327
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry. · full record | OpenQuestion